Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its ...
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
As STAT’s Katie Palmer reports in a new story, the lack of standards for collection of this information will make it more ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
Lilly and Novartis have collectively pledged almost $3 billion to their partnerships with Isomorphic signed last year, which ...
AlphaFold’s success would pave the way for Isomorphic Labs, a spinoff focused on AI-driven drug discovery. Isomorphic was founded in 2021, but it wasn’t until yesterday that the company ...